Living Cell Technologies has teamed up with Centocor Research and Development, a Johnson & Johnson unit, to conduct research using its seaweed-based encapsulation technology. The agreement provides Centocor an exclusive option to secure the global license to use the technology in human cells for two years.
Injecting cardiac stem cells into the hearts of rats can help fix the damage caused by doxorubicin, a chemotherapy drug used in treating various forms of cancer, U.S. scientists found. They think the findings could pave the way for doctors to prescribe higher doses of chemotherapy treatments to cancer patients while treating their injured hearts with their own stem cells afterward.
U.S. researchers have identified three proteins that appear to indicate the development of ovarian cancer three years before diagnosis. However, the proteins do not seem to reach the levels wherein the disease could be diagnosed at an early stage through screening.
The FDA agreed to review Valeant Pharmaceuticals' application for epilepsy drug Retigabine, the specialty drugmaker announced Wednesday. Retigabine showed promise in late-stage trials, in which the treatment reduced rates of partial-onset seizures when taken three times a day.
Novo Nordisk said the FDA postponed a formal feedback for diabetes drug liraglutide but it expects to hear from the agency within weeks. "We have an ongoing dialogue, and nothing new or sensational has occurred during this dialogue, so we are convinced that this is merely an expression that the process of approval is just taking longer than we originally anticipated," a company spokesman said.